Approval · Notice of Compliance 203 · 2002
ZIAGEN: Notice of Compliance 203
Issued July 19, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 203
- Date
- July 19, 2002
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication - pediatric use
- Therapeutic class
- Antiretroviral agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZIAGEN | Not yet assigned | — |
Medicinal ingredients
- ABACAVIR SULFATE 300 MG per TAB
- ABACAVIR SULFATE 20 MG per ML